§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇨🇦Canada	🇺🇸United States
Authority & dossier
Regulatory authority	HC HPFB	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA, EMA, MHRA, TGA +2	—
Lead pathway (timeline & fees) — New Drug Submission (NDS) · New Drug Application — 505(b)(1)
Pathway name	New Drug Submission (NDS)	New Drug Application — 505(b)(1)
Approval timeline	300–365 days	304–365 days
Application fee	CAD 539,663	USD 4,310,002
Annual renewal	CAD 4,129	USD 416,734
Local representative	Not required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	No	No
Local responsible person	Yes	Yes
RP role	Canadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	4 designations	6 designations
Examples	Priority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Three categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	No periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Vanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–30 days	30–30 days
GCP standard	ICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	Canada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

CanadaHC HPFB
United StatesFDA

English submissions

CanadaYes
United StatesYes

CTD accepted

CanadaYes
United StatesYes

eCTD accepted

CanadaYes
United StatesYes

Reliance pathway

CanadaAvailable
United StatesNone

Reference agencies

CanadaFDA, EMA, MHRA, TGA +2
United States—

Lead pathway (timeline & fees) — New Drug Submission (NDS) · New Drug Application — 505(b)(1)

Pathway name

CanadaNew Drug Submission (NDS)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Canada300–365 days
United States304–365 days

Application fee

CanadaCAD 539,663
United StatesUSD 4,310,002

Annual renewal

CanadaCAD 4,129
United StatesUSD 416,734

Local representative

CanadaNot required
United StatesNot required

Local manufacturing

CanadaNot required
United StatesNot required

GMP inspection

CanadaRequired
United StatesRequired

MAH & local presence

Local entity required

CanadaNo
United StatesNo

Local responsible person

CanadaYes
United StatesYes

RP role

CanadaCanadian Senior Officer responsible for the establishment licence, Quality Assurance Person (QA) for batch release, and Senior Medical Adviser for drug safety reporting. Canadian importer DEL holder takes physical receipt of imported products.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Canada4 designations
United States6 designations

Examples

CanadaPriority Review, Notice of Compliance with Conditions (NOC/c), Advance Consideration under Notice of Compliance +1
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

CanadaThree categories: Notifiable Changes (notification, certain low-risk changes), Supplemental NDS (S/NDS — prior approval, mid-tier and major changes), and Annual Notification (consolidates minor administrative updates). The Post-NOC Changes Quality Document and Post-NOC Changes Safety and Efficacy Document specify classification.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

CanadaNo periodic renewal of NDS — DIN remains valid indefinitely subject to compliance and payment of annual Right to Sell fee. Annual Drug Notification Form required to confirm marketing status.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

CanadaVanessa's Law (Protecting Canadians from Unsafe Drugs Act, 2014) significantly strengthened post-market authorities — including mandatory hospital ADR reporting (in force since 2019), authority to require label changes, and authority to require post-market studies. PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs) on harmonised birth dates. Canada Vigilance is the spontaneous reporting system; MedEffect Canada provides safety communications.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

CanadaAvailable
United StatesAvailable

Compassionate Use

CanadaAvailable
United StatesAvailable

Emergency Import

CanadaAvailable
United StatesAvailable

Parallel Import

CanadaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

CanadaRequired
United StatesRequired

Ethics approval

CanadaYes
United StatesYes

CTA timeline

Canada30–30 days
United States30–30 days

GCP standard

CanadaICH E6(R3) — Health Canada adopted via guidance update 2025; Division 5 FDR
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

CanadaRegulated
United StatesFree pricing

Reference pricing

CanadaYes
United StatesNo

HTA required

CanadaYes
United StatesNo

HTA body

CanadaCanada's Drug Agency (formerly CADTH, rebrand 2024); INESSS for Quebec
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding